Eva-karin Gidlund’s Post

In the high-risk world of drug development, staying ahead requires more than just innovation—it demands transformative technology. 💡 STB LaunchPad from Syntekabio is designed to revolutionize your drug discovery process. With our powerful independent supercomputing enabling our proprietary AI platform, we streamline your pipeline to deliver results faster and more efficiently. 🔍 Why choose STB LaunchPad? •Accelerated Discovery: Benefit from rapid identification of promising drug candidates, reducing time to market. You will have access to over 10 billion compounds as well as 1,400 in vitro/in vivo compatible drug targets •Enhanced Precision: Utilize our DeepMatcher® AI platform for highly accurate drug discovery across diverse therapeutic areas. DeepMatcher® utilizes Flexible Molecular Docking (FMD) to continuously capture protein-ligand interactions/poses •Broad Coverage: We cover more than 70% of human diseases •Proven Results: Providing you with superior outcomes achieved through our proprietary discovery platform and a network of successful industry collaborations •Save costs: Compounds validated before you make significant R&D investment Discover how our cutting-edge technology can transform your research and development 👉 https://lnkd.in/eXC4EuiF #DrugDiscovery #Clinical #Oncology #Biotechnology #Pharma #AI #Syntekabio

🌟 Meet our new community member: Ary Marsee from HepX Predict! 🌱 Last week, we kicked off our Science and Life Science Validation program. Stay tuned as we introduce our incredible lineup over the coming weeks! HepX Predict is revolutionizing drug development with patented 3D liver organoid technology. By bridging the gap between pre-clinical studies and clinical success, they're tackling the challenge of drug failures head-on. With 70-80% of drugs failing in human trials due to ineffective preclinical models, and liver toxicity contributing to over 20% of these failures, the need for accurate in vitro models is more crucial than ever. Here's to a future of safer and more effective drugs! 💊✨ #DrugDevelopment #Innovation #LifeScience

It’s not often that a reporter takes the time to ask about what drives your team to innovate and why at Juvena we decided to focus on secreted proteins. We are grateful to David Wild for the opportunity to reflect on how our CEO Dr. Hanadie Yousef's interests in biopharma innovation are shaping our approach to developing regenerative therapeutics for chronic and rare conditions. If you want to learn more about why we’re so excited to advance our pipeline and partner with large pharma to solve some of the greatest unmet needs of our time, check out the article linked below (subscription required). Here’s an excerpt from the article: "Juvena Therapeutics employs advanced computing to map the 4,000 proteins secreted by human cells. Through an AI-enabled platform, the company can identify potential protein-disease relationships and engineer medicines accordingly. By integrating AI, robotics and other cutting-edge technologies, Juvena accelerates preclinical screening and advances promising candidates to in-house clinical development. The platform has already generated an asset ready for clinical trials for Myotonic Dystrophy, a preclinical asset in obesity, and over 50 promising leads." #womeninbiotech #womeninlifescience #longevity https://lnkd.in/gnk7QaBd

Exciting highlights from Differentia’s CEO Dr. Kalyanasundaram Subramanian's Presentation at T20 Bio Tonacea Conference 2024! Dr. Subramanian delivered a game-changing keynote on “Applications of Quantitative Systems Pharmacology (QSP) in ADC New Drug Development,” showcasing how QSP is revolutionizing drug discovery and development. Key Takeaways: Modeling in Drug Development: Unveiling the power of modeling to boost efficiency and success rates in drug discovery. Groundbreaking Applications: From target selection and lead optimization to therapeutic window characterization, the insights were profound. Model-Informed Drug Development (MIDD): Dr. Subramanian emphasized MIDD's role in decoding disease mechanisms, fine-tuning dosing regimens, and enhancing patient segmentation. Dr. Subramanian's presentation was a thrilling glimpse into the future of #DrugDevelopment, promising a new era of innovation and efficiency that will ultimately benefit patients worldwide. Read more highlights of Dr. Subramanian's keynote here: https://lnkd.in/eWEXgTw7 #PharmaInnovation #Biotech #PKPD #MIDD #Pharmacometrics #MechanisticModeling #AI #QSPModeling

Are you ready to accelerate your drug discovery with AI-driven solutions designed to minimize risk and maximize results? At Syntekabio we are investing in your success with our unique Develop Now, Pay Later offer - enabling fast hit and lead discovery, allowing you to focus on achieving breakthroughs. Start today with a complimentary feasibility study of your target proteins! 🧬 Benefit from: •In-depth evaluation: Leverage our advanced AI and supercomputing technology to assess the viability of your targets without any upfront costs. •Key insights: Gain valuable data on your compounds' potential, helping you make informed decisions before committing resources. •No financial commitment: You only pay once you obtain the agreed upon validated results 📋 Contact us today to schedule your complimentary Feasibility Study and accelerate your drug discovery process: https://lnkd.in/eXC4EuiF #DrugDiscovery #Clinical #Oncology #Biotechnology #Pharma #AI #Syntekabio

Biomarker discovery and development is not only a powerful tool for developing better and more personalized #diagnostics, but is also an effective way to de-risk your future #drugdevelopment activities. And, thanks to advances in #omics technologies, the possibilities for profiling biological molecules across different states and conditions has been truly revolutionized - advancing data-driven biomarker #RandD. But how to make sense of these vast stores of omics #data in a way that is accessible to scientists and clinicians? For some hints, check out our white paper on #data driven biomarker R&D 👀👉https://lnkd.in/eaSJypGG

Discover how organoids bridge the gap between the lab and clinic Developing new drugs is a complex and often lengthy process. A major roadblock lies in the limitations of traditional preclinical models, which often fail to accurately represent the intricate biology of human patients. Join DDW for a free event on 18 June, 3PM BST to learn more about how patient-derived organoids are revolutionising drug discovery. https://lnkd.in/eEC865ka #Organoids #DrugDiscovery #LifeSciences HUB Organoids

🌱 🌱 Check out this #HighlyCitedPaper# by Peter Hamar et al: "Recent Preclinical and Clinical Progress in Liposomal Doxorubicin" You can find it at: https://lnkd.in/gnRUNmWp

If you are at BIO thsi year make sure you set aside some time to attend Pattern Computer presentation. Pattern uses a unique way of using machine learning to discover patterns in massive unstructured data.

Discover how Lifebit is driving efficiency in drug discovery with our latest module. By harnessing external expertise and cutting-edge technologies, we're working to accelerate the path to novel therapeutics. Explore the insights in our latest white paper: https://bit.ly/3w7mQOU #DrugDiscoveryWorkflows #Pharma #Lifebit